Chiasma
Latest round
- Series E
Last raised
- Feb 2015
Total raised
- $173M
Investors
- 11
About Chiasma
Chiasma is a biopharmaceutical company focused on developing innovative therapeutics to improve patient outcomes.Chiasma, founded in 2001 in Jerusalem, Israel, is a biopharmaceutical company dedicated to improving the lives of patients with chronic diseases. The company was co-founded by Asif Abbas and Marcel Craven.Chiasma specializes in delivering innovative therapeutic solutions, particularly in the biopharmaceutical sector. Their core product offerings focus on advanced drug delivery systems designed to enhance patient compliance and treatment efficacy. These products address specific challenges in the management of chronic diseases, ensuring patients receive effective therapies while minimizing the complexity of treatment regimens.Chiasma operates on a revenue model primarily geared towards pharmaceutical sales, providing access to groundbreaking therapies through specialized distribution channels. Their strategic partnerships with healthcare providers ensure that their innovative products reach patients effectively.Chiasma is focused on expanding its product line with planned launches of new therapies designed to address unmet medical needs in chronic disease management by 2025. The company is strategically targeting expansion into markets in Europe and Asia-Pacific to leverage increasing demand for innovative biopharmaceutical solutions.
Who invested in Chiasma
11 investors across 6 rounds
See all investors in Chiasma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Chiasma
Who invested in Chiasma?
Chiasma has 11 investors on record across 6 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Chiasma raised?
Chiasma has raised 6 venture rounds. Sign up free to see how much each round raised and the total.
When did Chiasma last raise money?
Chiasma's most recent round on record is a Series E, in Feb 2015.
What does Chiasma do?
Chiasma is a biopharmaceutical company focused on developing innovative therapeutics to improve patient outcomes.
Where is Chiasma headquartered?
Chiasma is headquartered in Jerusalem, Israel.
Which VCs invest in companies like Chiasma?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Chiasma's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series E
Raising like Chiasma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.